The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021
Open accessAbstract
As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days). On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Moderna COVID-19 vaccine administered as 2 doses, 1 month apart to prevent COVID-19. On December 19, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of Moderna COVID-19 vaccine (1). As of January 10, 2021, a reported 4,041,396 first doses of Moderna COVID-19 vaccine had been administered in the United States, and reports of 1,266 (0.03%) adverse events after receipt of Moderna COVID-19 vaccine were submitted to the Vaccine Adverse Event Reporting System (VAERS). Among these, 108 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis. Anaphylaxis is a life-threatening allergic reaction that occurs rarely after vaccination, with onset typically within minutes to hours (2). Among these case reports, 10 cases were determined to be anaphylaxis (a rate of 2.5 anaphylaxis cases per million Moderna COVID-19 vaccine doses administered), including nine in persons with a documented history of allergies or allergic reactions, five of whom had a previous history of anaphylaxis. The median interval from vaccine receipt to symptom onset was 7.5 minutes (range = 1-45 minutes). Among eight persons with follow-up information available, all had recovered or been discharged home. Among the remaining case reports that were determined not to be anaphylaxis, 47 were assessed to be nonanaphylaxis allergic reactions, and 47 were considered nonallergic adverse events. For four case reports, investigators have been unable to obtain sufficient information to assess the likelihood of anaphylaxis. This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Moderna COVID-19 vaccine during December 21, 2020-January 10, 2021, in the United States. CDC has issued updated interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States (3) and interim considerations for preparing for the potential management of anaphylaxis (4).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Shimabukuro, T. T., Nguyen, M., Martin, D., & DeStefano, F. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.035 · Cited by 608
CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7002e1 · Cited by 479
Self-citationRüggeberg, J. U., Gold, M. S., Bayas, J.-M., Blum, M. D., Bonhoeffer, J., Friedlander, S., de Souza Brito, G., Heininger, U., Imoukhuede, B., Khamesipour, A., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.064 · Cited by 383
Rossen, L. M., Branum, A. M., Ahmad, F. B., Sutton, P., & Anderson, R. N. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6942e2 · Cited by 372
Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M., Curran, K. G., Chamberland, M., McClung, N., Campos-Outcalt, D., Morgan, R. L., Mbaeyi, S., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm695152e1 · Cited by 317
Vaccine-associated hypersensitivity
McNeil, M. M., & DeStefano, F. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.971 · Cited by 273
The reporting sensitivities of two passive surveillance systems for vaccine adverse events.
Rosenthal, S., & Chen, R. (1995) · American Journal of Public Health · doi:10.2105/ajph.85.12.1706 · Cited by 201
Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016
Su, J. R., Moro, P. L., Ng, C. S., Lewis, P. W., Said, M. A., & Cano, M. V. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.12.1003 · Cited by 118
Cited by
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study
Gray, K. J., Bordt, E. A., Atyeo, C., Deriso, E., Akinwunmi, B., Young, N., Baez, A. M., Shook, L. L., Cvrk, D., James, K., et al. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.03.023 · Cited by 699
Shimabukuro, T. T., Cole, M., & Su, J. R. (2021) · JAMA · doi:10.1001/jama.2021.1967 · Cited by 475
Ibrahim, M., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., Elgarhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 465
Covid‐19 vaccines and variants of concern: A review
Hadj Hassine, I. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2313 · Cited by 383
Metadata
- Authors
- CDC COVID-19 Response Team, & Administration, F. A. D.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2021-01-29
- Volume
- 70
- Issue
- 4
- Pages
- 125-129
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- OpenAlex
- W3125874619
- Cited by
- 269
- References
- 8
- FWCI
- 19.18
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021. https://app.cochat.ai/papers/10.15585/mmwr.mm7004e1
- The paper
- CDC COVID-19 Response Team, & Administration, F. A. D. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7004e1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.